Le Lézard
Classified in: Health
Subjects: CCA, TDS, FVT

Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences


DUBLIN, Aug. 29, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences. 

A live audio webcast of each presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at http://www.jazzpharmaceuticals.com.  Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company's website at http://www.jazzpharmaceuticals.com.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs.  The company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.  In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Defitelio® (defibrotide sodium) and Vyxeos® (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Erwinase® and Defitelio® (defibrotide) in countries outside the U.S.  For country-specific product information, please visit http://www.jazzpharmaceuticals.com/products.  For more information, please visit http://www.jazzpharmaceuticals.com/ and follow us on Twitter at @JazzPharma.

Jazz Pharmaceuticals Logo

Logo - https://mma.prnewswire.com/media/272253/Jazz_Pharmaceuticals_Logo.jpg


These press releases may also interest you

at 18:00
Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance to MamaLift PlusTM. MamaLift Plus is the first prescription digital therapeutic for the treatment of postpartum depression (PPD), a...

at 17:45
BioSyent Inc. ("BioSyent", TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Showcase in Las Vegas, Nevada between April 30th ? May 2nd at the Paris Hotel & Casino. Mr. René Goehrum, President and CEO of BioSyent,...

at 17:44
United Breast Cancer Foundation (UBCF) is proud to host a heartfelt event dedicated to honor the memory of Audrey Beverly Christy Mastroianni, a remarkable Rhode Island woman who bravely battled breast cancer. The "Gifts of Comfort and Hope" Mattress...

at 17:31
DRI Healthcare Trust (the "Trust") announces the closing of its previously announced preferred securities refinancing, whereby its US$114,760,000 aggregate principal amount of Series A and Series B preferred securities and 6,369,180 warrants were...

at 17:31
DelveInsight's Corneal Implant Market...

at 17:26
In observance of National Infertility Awareness Week (April 21-27, 2024), Inception Fertilitytm, a global leader of fertility services, and The Prelude Network®, Inception's clinical network and the largest network of fertility providers in North...



News published on and distributed by: